Skip to content

PE-22-28 vs Selank

Updated 5 sources

Key differences

  1. 1PE-22-28 targets mood through TREK-1; Selank is used for anxiety through GABA-linked effects.
  2. 2Community users pair them as a mood stack.

Side by side

Facts from each record, in the same words as their own pages.
PE-22-28 and Selank side by side
PE-22-28Selank
Category
  • Cognitive
  • Cognitive, Sleep
Evidence
  • Animal data only
  • Limited human data
FDA status
  • Not FDA approvedRegulatory
  • Not FDA approvedRegulatory
WADA
  • Not confirmed
  • Not confirmed
Half-life
  • Not published. Described as relatively short in serum in vitro; the 23 hour effect half-time often quoted belongs to modified analogs in mice.Clinical study
  • Minutes. Per the Russian label, nasal Selank shows in plasma within 30 seconds and its level falls over 5 to 5.5 minutes. Nothing shows up in urine.Regulatory
Routes
  • Nasal, Subcutaneous injection
  • Nasal, Subcutaneous injection
Forms
  • Vial (powder), Nasal spray
  • Nasal spray, Vial (powder)
Reported doses
  • 100 to 500 mcg (nasal)
  • 50 to 500 mcg (subcutaneous injection)
  • 150 to 2,700 mcg (nasal)
  • 200 to 1,000 mcg (subcutaneous injection)
Most cited frequency
  • Once daily, in the morning
  • Once daily
Vial sizes
  • 8 mg, 10 mg, 20 mgVendor guide
  • 5 mg, 10 mg, 30 mgCompetitor guide
Mixed vial keeps
  • Fridge at 2 to 8 C, away from light.Competitor guide
  • Guides disagree on how long mixed Selank keeps: 2 to 3 weeks, 3 to 4 weeks, or 21 to 30 days.Competitor guide
Protocols on file
  • 8
  • 24

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

5 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.

Regulatory4

  1. Selank 0.15% nasal drops (Russian label)Vidal, via a reference work · checked Oct 24, 2026
  2. Selank instruction for use (Russian label)selank.ru (Peptogen), archived copy, via a vendor guide · checked Oct 24, 2026
  3. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026)FDA · checked Oct 24, 2026
  4. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety RisksFDA · checked Oct 24, 2026